Radioterapia más temozolomida o PCV en pacientes con oligodendroglioma anaplásico con codeleción 1p19q

González-Aguilar, Alberto; Reyes-Moreno, Ignacio; Peiro-Osuna, R P; Hernández-Hernández, Alan; Gutierrez-Aceves, A; Santos-Zambrano, J; Guerrero-Juárez, Vicente; López-Martínez, Manuel; Castro-Martínez, Elvira

doi:10.33588/rn.6708.2018009

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the PCV regimen is associated with a higher toxicity profile and requires more frequent hospital visits for intravenous vincristine and multiple-dose oral medication schedule [ 23 24 ]. On the other hand, radiotherapy with concurrent and adjuvant temozolomide has a relatively lower toxicity profile and a simpler dosing schedule without intravenous drug administration [ 26 ]. The initial results of the ongoing CODEL phase III randomized trial indicate a 5-year overall survival rate of 91% in patients receiving concurrent and adjuvant temozolomide in combination with radiotherapy in 1p19q codeleted oligodendroglioma [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Recommendation Using the Delphi Method (Version 2023.1)

Kim

Wee

et al. 2023

Brain Tumor Res Treat

View full text Add to dashboard Cite

Background During the coronavirus disease 2019 (COVID-19) pandemic, the need for appropriate treatment guidelines for patients with brain tumors was indispensable due to the lack and limitations of medical resources. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, has undertaken efforts to develop a guideline that is tailored to the domestic situation and that can be used in similar crisis situations in the future. Methods The KSNO Guideline Working Group was composed of 22 multidisciplinary experts on neuro-oncology in Korea. In order to reach consensus among the experts, the Delphi method was used to build up the final recommendations. Results All participating experts completed the series of surveys, and the results of final survey were used to draft the current consensus recommendations. Priority levels of surgery and radiotherapy during crises were proposed using appropriate time window-based criteria for management outcome. The highest priority for surgery is assigned to patients who are life-threatening or have a risk of significant impact on a patient’s prognosis unless immediate intervention is given within 24–48 hours. As for the radiotherapy, patients who are at risk of compromising their overall survival or neurological status within 4–6 weeks are assigned to the highest priority. Curative-intent chemotherapy has the highest priority, followed by neoadjuvant/adjuvant and palliative chemotherapy during a crisis period. Telemedicine should be actively considered as a management tool for brain tumor patients during the mass infection crises such as the COVID-19 pandemic. Conclusion It is crucial that adequate medical care for patients with brain tumors is maintained and provided, even during times of crisis. This guideline will serve as a valuable resource, assisting in the delivery of treatment to brain tumor patients in the event of any future crisis.

show abstract

Section: Discussionmentioning

confidence: 99%

The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Recommendation Using the Delphi Method (Version 2023.1)

Kim

Wee

et al. 2023

Brain Tumor Res Treat

View full text Add to dashboard Cite

show abstract

“…At the same time, the 10-year risk of histological progression to grade 3 was lowest in the PCV-treated group (9%), compared with 75% in the TMZ-treated group. When combined with radiotherapy, data from forty-eight Latin American patients with 1p/19q co-deleted anaplastic oligodendroglioma showed statistically significantly improved PFS (7.2 versus 6.1 years) and OS (10.6 versus 9.2 years) in patients receiving PCV relative to TMZ ( 163 ). Analogous results were reported in a French study in 311 patients with IDH-mutant anaplastic astrocytoma, in whom the 4-year PFS was 70.8% if treated with radiotherapy and PCV and only 53.5% if treated with radiotherapy and TMZ (HR 0.58[95% CI 0.38 to 0.87], p-value=0.0074) ( 164 ).…”

Section: Treating Gliomamentioning

confidence: 99%

“…Similarly, an extremely high toxicity-related discontinuation rate of 75.8% was reported for PCV, compared with 39.5% for TMZ (p-value for difference<0.001). In a Spanish retrospective study of patients with 1p/19q-codeleted anaplastic oligodendroglioma, grade 3/4 were also reported to be more frequent in the PCV versus the TMZ group (42.8 versus 11.1%, p-value<0.0016) ( 163 ). Less than half (42.8%) of patients completed their PCV protocol, compared with 80.2% of patients completing their TMZ protocol.…”

Section: Treating Gliomamentioning

confidence: 99%

High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma

Pöhlmann,

Weller,

Marcellusi

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Gliomas are a group of heterogeneous tumors that account for substantial morbidity, mortality, and costs to patients and healthcare systems globally. Survival varies considerably by grade, histology, biomarkers, and genetic alterations such as IDH mutations and MGMT promoter methylation, and treatment, but is poor for some grades and histologies, with many patients with glioblastoma surviving less than a year from diagnosis. The present review provides an introduction to glioma, including its classification, epidemiology, economic and humanistic burden, as well as treatment options. Another focus is on treatment recommendations for IDH-mutant astrocytoma, IDH-mutant oligodendroglioma, and glioblastoma, which were synthesized from recent guidelines. While recommendations are nuanced and reflect the complexity of the disease, maximum safe resection is typically the first step in treatment, followed by radiotherapy and/or chemotherapy using temozolomide or procarbazine, lomustine, and vincristine. Immunotherapies and targeted therapies currently have only a limited role due to disappointing clinical trial results, including in recurrent glioblastoma, for which the nitrosourea lomustine remains the de facto standard of care. The lack of treatment options is compounded by frequently suboptimal clinical practice, in which patients do not receive adequate therapy after resection, including delayed, shortened, or discontinued radiotherapy and chemotherapy courses due to treatment side effects. These unmet needs will require significant efforts to address, including a continued search for novel treatment options, increased awareness of clinical guidelines, improved toxicity management for chemotherapy, and the generation of additional and more robust clinical and health economic evidence.

show abstract

Anaplasti̇k Oli̇godendrogli̇omada Görüntüleme Yöntemleri̇ni̇n Radyoterapi̇ Tedavi̇ Volümünü Beli̇rlemedeki̇ Etki̇si̇

Akın¹,

DUZOVA

2022

Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi

View full text Add to dashboard Cite

Abstract Objective: Utility of radiation therapy (RT) has been well established for management of World Health Organization (WHO) grade 3 anaplastic oligodendroglioma. Nevertheless, optimal target definition for radiotherapeutic management of WHO grade 3 anaplastic oligodendroglioma requires elucidation. Within this context, treatment volume determination for WHO grade anaplastic oligodendroglioma based on multimodality imaging is assessed in this original research article. Materials and methods: Treatment volume determination for RT by incorporation of MRI or by CT-simulation images only was comparatively assessed for patients receiving RT for WHO grade 3 anaplastic oligodendroglioma in this original research article. Results: VersaHD (Elekta, UK) Linear Accelerator (LINAC) was used for treatment with 6 MV photons. IGRT techniques were utilized for treatment verification. Ground truth target volume was used as the reference for actual treatment and for comparison purposes, and it was determined after meticulous evaluation on an individual basis. Primary outcome measure of the study was comparative assessment of treatment volume determination by either CT-only imaging and by CT-MR fusion based imaging. This study revealed that the ground truth target volume was identical with treatment volume definition by CT-MR fusion based imaging. Conclusion: This study reveals improved treatment volume determination for WHO grade 3 anaplastic oligodendrogliomas by incorporation of MRI in the treatment planning procedure. Clearly, further studies are warranted to shed light on this issue.

show abstract

Radioterapia más temozolomida o PCV en pacientes con oligodendroglioma anaplásico con codeleción 1p19q

Cited by 3 publications

References 0 publications

The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Recommendation Using the Delphi Method (Version 2023.1)

The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Recommendation Using the Delphi Method (Version 2023.1)

High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma

Anaplasti̇k Oli̇godendrogli̇omada Görüntüleme Yöntemleri̇ni̇n Radyoterapi̇ Tedavi̇ Volümünü Beli̇rlemedeki̇ Etki̇si̇

Contact Info

Product

Resources

About